Ironwood Pharmaceuticals/$IRWD
1D1W1MYTD1Y5YMAX
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
- Ticker
- $IRWD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 100
- Headquarters
- Boston, United States
- Website
- ironwoodpharma.com
IRWD Metrics
BasicAdvanced
$720M
5.53
$0.79
0.21
-
Price and volume
Market cap
$720M
Beta
0.21
52-week high
$5.78
52-week low
$1.01
Average daily volume
2.3M
Financial strength
Current ratio
6.063
Quick ratio
5.84
Long term debt to equity
-243.187
Total debt to equity
-245.217
Interest coverage (TTM)
7.23%
Profitability
EBITDA (TTM)
238.105
Gross margin (TTM)
77.22%
Net profit margin (TTM)
33.36%
Operating margin (TTM)
60.69%
Effective tax rate (TTM)
37.38%
Revenue per employee (TTM)
$3,890,000
Management effectiveness
Return on assets (TTM)
47.01%
Return on equity (TTM)
-55.26%
Valuation
Price to earnings (TTM)
5.526
Price to revenue (TTM)
1.827
Price to book
-4.45
Price to tangible book (TTM)
-4.41
Price to free cash flow (TTM)
3.833
Free cash flow yield (TTM)
26.09%
Free cash flow per share (TTM)
1.137
Growth
Revenue change (TTM)
26.19%
Earnings per share change (TTM)
-1,650.82%
3-year revenue growth (CAGR)
-3.05%
10-year revenue growth (CAGR)
6.20%
3-year earnings per share growth (CAGR)
-49.02%
10-year earnings per share growth (CAGR)
1.61%
What the Analysts think about IRWD
Analyst ratings (Buy, Hold, Sell) for Ironwood Pharmaceuticals stock.
IRWD Financial Performance
Revenues and expenses
IRWD Earnings Performance
Company profitability
IRWD News
AllArticlesVideos
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat2 weeks ago
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Business Wire2 weeks ago
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.